Kiniksa Pharmaceuticals Schedules 2024 Annual Meeting and Special Redomiciliation Meeting

TL;DR

<b>Kiniksa Pharmaceuticals is holding its 2024 Annual Meeting and a Special Meeting to vote on a proposed redomiciliation from Bermuda to the UK.</b>

AI Summary

Kiniksa Pharmaceuticals, Ltd. (KNSA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Kiniksa Pharmaceuticals, Ltd. will hold its 2024 Annual Meeting of Shareholders on June 5, 2024, at 10:00 a.m. Atlantic Time. A Special Court-Ordered Meeting of Shareholders will also be held on June 5, 2024, immediately following the Annual Meeting. Both meetings will be conducted virtually via live webcast. The purpose of the Special Meeting is to approve a proposal to change Kiniksa's place of incorporation from Bermuda to the United Kingdom. Shareholders are encouraged to vote their shares regardless of attendance.

Why It Matters

For investors and stakeholders tracking Kiniksa Pharmaceuticals, Ltd., this filing contains several important signals. Shareholders will vote on a significant corporate restructuring, changing the company's place of incorporation from Bermuda to the United Kingdom. The virtual format allows for broad shareholder participation in key governance decisions.

Risk Assessment

Risk Level: — Kiniksa Pharmaceuticals, Ltd. shows moderate risk based on this filing. The filing is a routine proxy statement for annual shareholder meetings and a corporate restructuring vote, with no immediate financial or operational performance indicators presented.

Analyst Insight

Shareholders should review the proxy materials carefully to understand the implications of the proposed redomiciliation and vote accordingly.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Shareholders)
• June 5 — Meeting Date (Date for both the Annual Meeting and Redomiciliation Meeting)
• 10:00 a.m. Atlantic Time — Annual Meeting Time (Scheduled start time for the Annual Meeting)

Key Players & Entities

• Kiniksa Pharmaceuticals, Ltd. (company) — Registrant and filer of the proxy statement
• June 5, 2024 (date) — Date of the Annual Meeting and Redomiciliation Meeting
• Bermuda (location) — Current place of incorporation
• United Kingdom (location) — Proposed place of incorporation

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The filing must adhere to all rules and regulations set forth by the Securities and Exchange Commission for proxy statements.

Industry Context

Kiniksa Pharmaceuticals operates in the pharmaceutical preparations industry. This filing concerns corporate governance and structural changes.

Regulatory Implications

The filing is made in accordance with Section 14(a) of the Securities Exchange Act of 1934, requiring companies to provide shareholders with information before soliciting their votes.

What Investors Should Do

1. Review the proxy statement for details on the redomiciliation proposal.
2. Attend the virtual meetings on June 5, 2024, or vote by proxy.
3. Understand the implications of changing the company's place of incorporation.

Key Dates

• 2024-06-05: 2024 Annual Meeting of Shareholders — Shareholders will vote on company matters.
• 2024-06-05: Special Court-Ordered Meeting of Shareholders (Redomiciliation Meeting) — Shareholders will vote on changing the company's place of incorporation from Bermuda to the UK.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This filing type indicates the company is providing official notice and details for shareholder meetings and votes.)

Redomiciliation

The process of changing a company's legal domicile from one jurisdiction to another. (This is a key proposal being voted on by shareholders at the Special Meeting.)

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard proxy statement for annual meetings and specific proposals, not a report on financial performance compared to a previous period.

Key Financial Figures

• $0.000273235 — uda Class A common shares, par value of $0.000273235 per share 1 TABLE OF CONTENTS Pro

Filing Documents

• tm242724d7_def14a.htm (DEF 14A) — 3246KB
• fc_shareholder-bw.jpg (GRAPHIC) — 64KB
• ic_arrow-bw.jpg (GRAPHIC) — 2KB
• ic_men-bw.jpg (GRAPHIC) — 1KB
• bc_capvstsr-4c.jpg (GRAPHIC) — 67KB
• bc_capvsnetincome-4c.jpg (GRAPHIC) — 72KB
• px_kinikaproxy1pg01-bw.jpg (GRAPHIC) — 266KB
• px_kinikaproxy1pg02-bw.jpg (GRAPHIC) — 264KB
• px_kinikaproxy1pg03-bw.jpg (GRAPHIC) — 213KB
• px_kinikaproxy1pg04-bw.jpg (GRAPHIC) — 280KB
• 0001104659-24-050621.txt (&nbsp;) — 7289KB
• knsa-20231231.xsd (EX-101.SCH) — 11KB
• knsa-20231231_def.xml (EX-101.DEF) — 7KB
• knsa-20231231_lab.xml (EX-101.LAB) — 41KB
• knsa-20231231_pre.xml (EX-101.PRE) — 13KB
• tm242724d7_def14a_htm.xml (XML) — 151KB

Risk Factors

Risk Factors 25 Special Note Regarding Forward-Looking Statements 27 Annual Meeting Matters Laying of Financial Statements 29 Annual Meeting Proposals to be Voted On 30 Annual Meeting Proposal No. 1—Election of Directors 30 Annual Meeting Proposal No. 2—Appointment of Auditor, Delegation to our Board of Directors, through our Audit Committee, of the Authority to Set the Auditor's Remuneration, and Ratification of the Appointment of Independent Registered Public Accounting Firm 34 Annual Meeting Proposal No. 3—Advisory Vote on Executive Compensation 35 Report of the Audit Committee of the Board of Directors 37 Independent Registered Public Accounting Firm Fees and Other Matters 38 Corporate Governance 39 General 39 Board Composition 39 TABLE OF CONTENTS Table of Contents continued Board Diversity 39 Director Independence 40 Director Candidates 40 Communications from Shareholders 41 Board Leadership Structure 41 Board Role in Risk Oversight 42 Board Evaluation 43 Code of Ethics 43 Insider Trading Compliance Policy 43 Attendance by Members of the Board of Directors at Meetings 43 Committees of the Board of Directors 44 Audit Committee 44 Compensation Committee 45 Nominating and Corporate Governance Committee 46 Science and Research Committee 46 Executive Officers 47 Executive and Director Compensation 49

Executive Compensation

Executive Compensation 49 2023 Summary Compensation Table 49 Narrative Disclosure to Summary Compensation Table 49 Outstanding Equity Awards at 2023 Fiscal Year End 52 Employment Agreements 53 Pay versus Performance Table (2021-2023) 55 Director Compensation 59 2023 Director Compensation Table 61 Equity Compensation Plan Information 62

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 63 Certain Relationships 67 Redomiciliation Meeting Proposals to be Voted On 69 Redomiciliation Meeting Proposal No. 1-Approval of Scheme of Arrangement 69 Redomiciliation Meeting Proposal No. 2-Approval of Motion to Adjourn Redomiciliation Meeting 70 The Redomiciliation 71 Background and Reasons for the Redomiciliation 71 Amendment, Termination or Delay 72 Conditions to Consummation of the Redomiciliation 72 Court Sanction of the Scheme of Arrangement 73 Federal Securities Law Consequences; Resale Restrictions 74 TABLE OF CONTENTS Table of Contents continued Effective Date and Redomiciliation Time 75 Management of New Kiniksa 75 Deeds of Indemnification 75 Interests of Certain Persons in the Redomiciliation 76 Regulatory Matters 76 No Appraisal Rights 76 Exchange of Shares 76 Dividend Policy 76 Stock Exchange Listing 77 Accounting Treatment of the Redomiciliation 77 Certain United States, United Kingdom and Bermuda Tax Considerations 78 U.S. Federal Income Tax Considerations 78 U.K. Tax Considerations 84 Bermuda Tax Considerations 87 Description of New Kiniksa Shares 88 Capital Structure 88 Preemption Rights, Share Warrants and Share Options 89 Dividends 89 Share Buybacks and Redemptions 90 Bonus Shares 91 Consolidation and Division; Subdivision 91 Reduction of Share Capital 91 General Meetings of Shareholders 91 Voting 92 Variation of Class Rights Attaching to Shares 93 Quorum for General Meetings 93 Inspection of Books and Records 93 Acquisitions and Appraisal Rights 94 Disclosure of Interests in Shares 94 Anti-Takeover Provisions 94 Corporate Governance 97 Legal Name; Formation; Fiscal Year; Registered Office 97 Duration; Dissolution; Rights upon Liquidation 98 Exchange of Shares 98 Stock Exchange Listing 98 No Sink

Executive Compensation Highlights

Executive Compensation Highlights Our Compensation Committee, which reviews our compensation programs, practices and policies, is committed to effective compensation governance. Listed below are some of the executive compensation practices and policies designed to drive performance, mitigate against undue risk and to align the interests of our executives and other employees with those of our shareholders. What We Do Provide a Mix of Fixed and Variable Compensation, with Emphasis on Variable Compensation Provide a Mix of Annual- and Long-Term Incentive Compensation, with Emphasis on Long-Term Incentive Compensation Engage Independent Compensation Consultants Design Compensation Programs to Have a Strong Link Between Performance Measures and Strategic Objectives Utilize Competitive Market Data and a Compensation Peer Group Maintain Policy Prohibiting Hedging and Pledging What We Don't Do No Excise Tax Gross-Ups in Existing Agreements No Pension or Executive Retirement Plans No Automatic Single Trigger Equity Acceleration on Change of Control No Repricing or Cash Buyouts of Underwater Options Without Shareholder Approval No Discount Share Options No Excessive Perquisites 3 TABLE OF CONTENTS Proxy Statement for Annual Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda This proxy statement is furnished in connection with the solicitation by the Board of Directors ("Board" or "Board of Directors") of Kiniksa Bermuda, of proxies to be voted at the Annual Meeting to be held on June 5, 2024 at 10:00 a.m. Atlantic Time (9:00 a.m. Eastern Time). The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online. Holders of record of our Class A Shares and Class B Shares (together, the "Annual Meeting Voting Shares"), as of the close of busine